REG - Surgical Innovations - Notice of results and trading update

Surgical InnovationsAnnouncement

27/03/2020 15:05

RNS Number : 9216H
  
Surgical Innovations Group PLC
  
27 March 2020
  
 

 
Surgical Innovations Group plc 
("SI" or the "Group")
 
Notice of results and trading update on the effects of Covid-19
 
Notice of results
Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery, announces that it will release its audited annual results for the year ended 31 December 2019 on Tuesday 31 March 2020. These have been delayed slightly from the planned timetable whilst the Group and its auditors have worked through the implications of regulatory guidance relating to Covid-19, including that published by the Financial Conduct Authority, on 22 March 2020.
 
As outlined in the trading update announced on 13 January 2020, the adjusted profit before tax for the year ended 31 December 2019 was in line with market expectations.
 
Trading update on the effects of Covid-19
On 17 March 2020, the UK Government announced the suspension of all non-urgent surgical procedures by the NHS in preparation for a peak in treatment of patients affected by Covid-19. This will have a significant adverse short-term effect on the Group's trading prospects in the UK market, and it is anticipated that other significant markets overseas may be affected in a similar manner.
 
The audited annual results will set out the approach taken by the Group in relation to the pandemic, and its likely effect on the Group's business and prospects in the current year. Full details will also be provided on actions taken by the Board and management to date to mitigate these effects, aiming to protect the longer-term trading prospects of the Group. Reflecting the current material uncertainty, the Group has withdrawn forecast guidance for the current financial year.
 
The Group has a positive net cash balance at the current time, and reasonable grounds to anticipate support from the UK Government, its bankers and other key stakeholders.
 
For further information please contact:
 



Surgical Innovations Group plc


www.sigroupplc.com




Nigel Rogers, Chairman 


Tel: 0113 230 7597




David Marsh, CEO


















N+1 Singer (NOMAD & Broker)


Tel: 020 7496 3000




Aubrey Powell (Corporate Finance)
Rachel Hayes (Corporate Broking)


















Walbrook PR (Financial PR & Investor Relations)


Tel: 020 7933 8780 or si@walbrookpr.com




Paul McManus / Lianne Cawthorne


Mob: 07980 541 893 / 07584 391 303



 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCBUGDXGGDDGGR